ClinicalTrials.gg
CompletedNCT02102932Updated Sep 24, 2015Results posted

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

A Phase 1 interventional study of 5 mg empagliflozin/850 mg metformin FDC and 12.5 mg empagliflozin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of Empagliflozin and metformin compared to the administration of single tablets (Empagliflozin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patient's compliance with antidiabetic treatment, in particular with concern to the frequent polypharmacy in diabetic patients.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy male and female subjects

Exclusion criteria

Exclusion criteria:

Any relevant deviation from healthy conditions

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    12.5 mg empagliflozin/850 mg metformin

    24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order

    Drug: 12.5 mg empagliflozin · Drug: 850 mg metformin · Drug: 12.5 mg empagliflozin/850 mg metformin FDC

  • Experimental
    5 mg empagliflozin/850 mg metformin

    24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order

    Drug: 5 mg empagliflozin/850 mg metformin FDC · Drug: 5 mg empagliflozin · Drug: 850 mg metformin

  • Experimental
    12.5 mg empagliflozin/500 mg metformin

    24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order

    Drug: 12.5 mg empagliflozin · Drug: 12.5 mg empagliflozin/500 mg metformin FDC · Drug: 500 mg metformin

  • Experimental
    5 mg empagliflozin/500 mg metformin

    24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order

    Drug: 5 mg empagliflozin · Drug: 5 mg empagliflozin/500 mg metformin FDC · Drug: 500 mg metformin

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-∞) for Empagliflozin

    Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity

    Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  2. AUC(0-∞) for Metformin

    Area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity

    Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  3. Cmax for Empagliflozin

    Maximum measured concentration of the empagliflozin in plasma

    Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  4. Cmax for Metformin

    Maximum measured concentration of the metformin in plasma

    Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

Secondary outcomes

  1. AUC(0-tz) of Empagliflozin

    Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 up to the last quantifiable data point

    Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  2. AUC(0-tz) of Metformin

    Area under the concentration-time curve of the metformin in plasma over the time interval from 0 up to the last quantifiable data point

    Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

07

Results

Posted Sep 24, 2015

Participant flow

The study was performed as an open-label, randomised, single-dose, two-way crossover trial consisting of four trial parts. In each trial part the aim was to investigate the relative bioavailability of the Test treatment (T) and to compare it with the Reference treatment (R).

Participant flow — Overall Study
MilestoneT1R1R1T1T2R2R2T2T3R3R3T3T4R4R4T4
Started1212121212121212
Completed1212121212121212
Not completed00000000

Outcome measures

PrimaryAUC(0-∞) for Empagliflozin

Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity

Time frame:
1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol * h/L
AUC(0-∞) for Empagliflozin
nmol * h/LT1 (FDC)R1 (FC)T2 (FDC)R2 (FC)T3 (FDC)R3 (FC)T4 (FDC)R4 (FC)
AUC(0-∞) for Empagliflozin4330 ± 16.64110 ± 15.31680 ± 22.01630 ± 21.14200 ± 20.34060 ± 18.61610 ± 16.51560 ± 17.7
Statistical analysis
  • T1 (FDC) vs R1 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 105.29 · 90% CI 101.92 to 108.78Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.
  • T2 (FDC) vs R2 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 103.23 · 90% CI 99.91 to 106.65Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.
  • T3 (FDC) vs R3 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 103.56 · 90% CI 99.73 to 107.54Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.
  • T4 (FDC) vs R4 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 102.81 · 90% CI 99.36 to 106.37Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.
PrimaryAUC(0-∞) for Metformin

Area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity

Time frame:
1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng * h/mL
AUC(0-∞) for Metformin
ng * h/mLT1 (FDC)R1 (FC)T2 (FDC)R2 (FC)T3 (FDC)R3 (FC)T4 (FDC)R4 (FC)
AUC(0-∞) for Metformin11600 ± 18.911100 ± 17.411700 ± 21.811000 ± 24.07800 ± 18.97510 ± 17.87030 ± 20.77340 ± 18.8
Statistical analysis
  • T1 (FDC) vs R1 (FC) · ANOVA · p = 0.0001 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 104.56 · 90% CI 97.56 to 112.07Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.
  • T2 (FDC) vs R2 (FC) · ANOVA · p = 0.0001 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 105.80 · 90% CI 99.32 to 112.70Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.
  • T3 (FDC) vs R3 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 103.75 · 90% CI 98.18 to 109.63Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.
  • T4 (FDC) vs R4 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 95.77 · 90% CI 89.88 to 102.03Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.
PrimaryCmax for Empagliflozin

Maximum measured concentration of the empagliflozin in plasma

Time frame:
1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol/L
Cmax for Empagliflozin
nmol/LT1 (FDC)R1 (FC)T2 (FDC)R2 (FC)T3 (FDC)R3 (FC)T4 (FDC)R4 (FC)
Cmax for Empagliflozin644 ± 18.2605 ± 15.3263 ± 17.7237 ± 20.7569 ± 22.1561 ± 25.3228 ± 16.4221 ± 22.2
Statistical analysis
  • T1 (FDC) vs R1 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 106.44 · 90% CI 100.44 to 112.80Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.
  • T2 (FDC) vs R2 (FC) · ANOVA · p = 0.0021 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 110.78 · 90% CI 103.80 to 118.24Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.
  • T3 (FDC) vs R3 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 101.38 · 90% CI 94.82 to 108.39Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.
  • T4 (FDC) vs R4 (FC) · ANOVA · p = 0.0002 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 103.02 · 90% CI 95.08 to 111.63Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.
PrimaryCmax for Metformin

Maximum measured concentration of the metformin in plasma

Time frame:
1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng/mL
Cmax for Metformin
ng/mLT1 (FDC)R1 (FC)T2 (FDC)R2 (FC)T3 (FDC)R3 (FC)T4 (FDC)R4 (FC)
Cmax for Metformin1920 ± 20.91830 ± 16.61950 ± 26.41840 ± 26.01290 ± 22.21230 ± 27.11150 ± 25.51190 ± 21.3
Statistical analysis
  • T1 (FDC) vs R1 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 104.91 · 90% CI 99.29 to 110.86Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.
  • T2 (FDC) vs R2 (FC) · ANOVA · p = 0.0008 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 106.32 · 90% CI 98.39 to 114.88Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.
  • T3 (FDC) vs R3 (FC) · ANOVA · p = 0.0003 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 104.44 · 90% CI 96.68 to 112.82Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.
  • T4 (FDC) vs R4 (FC) · ANOVA · p = 0.0004 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 96.61 · 90% CI 88.90 to 104.99Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.
SecondaryAUC(0-tz) of Empagliflozin

Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 up to the last quantifiable data point

Time frame:
1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol * h/L
AUC(0-tz) of Empagliflozin
nmol * h/LT1 (FDC)R1 (FC)T2 (FDC)R2 (FC)T3 (FDC)R3 (FC)T4 (FDC)R4 (FC)
AUC(0-tz) of Empagliflozin4270 ± 16.64060 ± 14.71650 ± 21.51600 ± 21.04140 ± 19.74010 ± 18.51580 ± 16.71540 ± 17.7
Statistical analysis
  • T1 (FDC) vs R1 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 105.16 · 90% CI 101.97 to 108.45Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.
  • T2 (FDC) vs R2 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 103.07 · 90% CI 99.75 to 106.50Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.
  • T3 (FDC) vs R3 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 103.14 · 90% CI 99.37 to 107.04Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.
  • T4 (FDC) vs R4 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 102.61 · 90% CI 99.10 to 106.25Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.
SecondaryAUC(0-tz) of Metformin

Area under the concentration-time curve of the metformin in plasma over the time interval from 0 up to the last quantifiable data point

Time frame:
1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng* h/mL
AUC(0-tz) of Metformin
ng* h/mLT1 (FDC)R1 (FC)T2 (FDC)R2 (FC)T3 (FDC)R3 (FC)T4 (FDC)R4 (FC)
AUC(0-tz) of Metformin11400 ± 19.210800 ± 17.611400 ± 23.110800 ± 25.17630 ± 18.97420 ± 17.96790 ± 24.77230 ± 18.3
Statistical analysis
  • T1 (FDC) vs R1 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 105.33 · 90% CI 99.34 to 111.68Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.
  • T2 (FDC) vs R2 (FC) · ANOVA · p = 0.0001 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 105.75 · 90% CI 99.09 to 112.85Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.
  • T3 (FDC) vs R3 (FC) · ANOVA · p = 0.0000 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 102.90 · 90% CI 97.11 to 109.03Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.
  • T4 (FDC) vs R4 (FC) · ANOVA · p = 0.0002 (P-value for ratio outside interval 80-125) · Ratio of the geometric means: 93.84 · 90% CI 87.74 to 100.36Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.

Adverse events

Collected over First drug administration until 7 days after last drug administration, up to 8 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T1 (FDC)—0/24 (0%)8/24 (33.3%)
R1 (FC)—0/24 (0%)8/24 (33.3%)
T2 (FDC)—0/24 (0%)9/24 (37.5%)
R2 (FC)—0/24 (0%)11/24 (45.8%)
T3 (FDC)—0/24 (0%)12/24 (50%)
R3 (FC)—0/24 (0%)11/24 (45.8%)
T4 (FDC)—0/24 (0%)7/24 (29.2%)
R4 (FC)—0/24 (0%)9/24 (37.5%)
Most frequent other events
Most frequent other events
EventT1 (FDC)R1 (FC)T2 (FDC)R2 (FC)T3 (FDC)R3 (FC)T4 (FDC)R4 (FC)
DiarrhoeaGastrointestinal disorders5/244/247/2411/2410/248/243/245/24
NauseaGastrointestinal disorders1/242/242/240/241/241/243/241/24
Bilirubin conjugated increasedInvestigations0/240/240/240/241/241/242/243/24
Blood bilirubin increasedInvestigations0/241/240/240/240/241/242/243/24
Glucose urine presentInvestigations3/240/240/240/240/240/240/240/24
Abdominal pain upperGastrointestinal disorders1/242/241/240/241/242/242/242/24
VomitingGastrointestinal disorders0/240/240/240/240/240/241/242/24
Blood bilirubin unconjugated increasedInvestigations0/241/240/240/240/241/241/242/24
DizzinessNervous system disorders0/240/240/240/240/240/242/240/24

Baseline characteristics

Treated set (TS): The TS included all subjects who were dispensed study medication and were documented to have received at least 1 dose of trial medication

Age, Continuous
Age, Continuous(years)T1R1R1T1T2R2R2T2T3R3R3T3T4R4R4T4Total
Mean26.9 ± 4.827.0 ± 5.326.8 ± 5.324.3 ± 3.424.8 ± 4.324.4 ± 3.924.6 ± 3.725.6 ± 4.825.5 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)T1R1R1T1T2R2R2T2T3R3R3T3T4R4R4T4Total
Female7575575748
Male5757757548
08

Study locations

1 site
  • 1276.23.86002 Boehringer Ingelheim Investigational Site
    Beijing, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2014
First posted
Apr 3, 2014
Start
May 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Sep 24, 2015
Last update
Sep 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02102932
Responsible party
Sponsor
First posted
Apr 3, 2014
Start date
May 2014
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Sep 24, 2015
Last update
Sep 24, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion